211 related articles for article (PubMed ID: 32948918)
1. Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker.
Joshi A; Guo J; Holleran JL; Kiesel B; Taylor S; Christner S; Parise RA; Miller BM; Ivy SP; Chu E; Venkataramanan R; Beumer JH
Cancer Chemother Pharmacol; 2020 Oct; 86(4):535-545. PubMed ID: 32948918
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers.
Jiko M; Yano I; Sato E; Takahashi K; Motohashi H; Masuda S; Okuda M; Ito N; Nakamura E; Segawa T; Kamoto T; Ogawa O; Inui K
Int J Clin Oncol; 2007 Aug; 12(4):284-90. PubMed ID: 17701008
[TBL] [Abstract][Full Text] [Related]
3. Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer.
Leijen S; Veltkamp SA; Huitema AD; van Werkhoven E; Beijnen JH; Schellens JH
Gynecol Oncol; 2013 Sep; 130(3):511-7. PubMed ID: 23665458
[TBL] [Abstract][Full Text] [Related]
4. Clearance of iohexol, chromium-51-ethylenediaminetetraacetic acid, and creatinine for determining the glomerular filtration rate in pigs with normal renal function: comparison of different clearance techniques.
Frennby B; Sterner G; Almén T; Chai CM; Jönsson BA; Månsson S
Acad Radiol; 1996 Aug; 3(8):651-9. PubMed ID: 8796729
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of paclitaxel and carboplatin in combination.
Kearns CM; Belani CP; Erkmen K; Zuhowski M; Hiponia D; Zacharski D; Engstrom C; Ramanathan R; Trenn MR; Aisner J
Semin Oncol; 1995 Oct; 22(5 Suppl 12):1-4; discussion 5-7. PubMed ID: 7481850
[TBL] [Abstract][Full Text] [Related]
6. A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel.
Calvert AH
Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-85-S2-90. PubMed ID: 9045345
[TBL] [Abstract][Full Text] [Related]
7. Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure.
Schmitt A; Gladieff L; Laffont CM; Evrard A; Boyer JC; Lansiaux A; Bobin-Dubigeon C; Etienne-Grimaldi MC; Boisdron-Celle M; Mousseau M; Pinguet F; Floquet A; Billaud EM; Durdux C; Le Guellec C; Mazières J; Lafont T; Ollivier F; Concordet D; Chatelut E
J Clin Oncol; 2010 Oct; 28(30):4568-74. PubMed ID: 20855828
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer.
Kroep JR; Giaccone G; Voorn DA; Smit EF; Beijnen JH; Rosing H; van Moorsel CJ; van Groeningen CJ; Postmus PE; Pinedo HM; Peters GJ
J Clin Oncol; 1999 Jul; 17(7):2190-7. PubMed ID: 10561275
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel and carboplatin combination chemotherapy in a hemodialysis patient with advanced ovarian cancer.
Watanabe M; Aoki Y; Tomita M; Sato T; Takaki Y; Kato N; Kikuchi M; Kase H; Tanaka K
Gynecol Oncol; 2002 Feb; 84(2):335-8. PubMed ID: 11812097
[TBL] [Abstract][Full Text] [Related]
10. Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions.
Calvert AH; Boddy A; Bailey NP; Siddiqui N; Humphreys A; Hughes A; Robson L; Gumbrell L; Thomas H; Chapman F
Semin Oncol; 1995 Oct; 22(5 Suppl 12):91-8; discussion 99-100. PubMed ID: 7481870
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer.
Belani CP; Kearns CM; Zuhowski EG; Erkmen K; Hiponia D; Zacharski D; Engstrom C; Ramanathan RK; Capozzoli MJ; Aisner J; Egorin MJ
J Clin Oncol; 1999 Feb; 17(2):676-84. PubMed ID: 10080614
[TBL] [Abstract][Full Text] [Related]
12. Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
Calvert AH; Newell DR; Gumbrell LA; O'Reilly S; Burnell M; Boxall FE; Siddik ZH; Judson IR; Gore ME; Wiltshaw E
J Clin Oncol; 2023 Oct; 41(28):4453-4454. PubMed ID: 37757592
[TBL] [Abstract][Full Text] [Related]
13. Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer.
Fogli S; Danesi R; De Braud F; De Pas T; Curigliano G; Giovannetti G; Del Tacca M
Ann Oncol; 2001 Nov; 12(11):1553-9. PubMed ID: 11822754
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer.
Boddy AV; Griffin MJ; Sludden J; Thomas HD; Fishwick K; Wright JG; Plumner ER; Highley M; Calvert AH
Cancer Chemother Pharmacol; 2001 Jul; 48(1):15-21. PubMed ID: 11488519
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer.
Shord SS; Faucette SR; Gillenwater HH; Pescatore SL; Hawke RL; Socinski MA; Lindley C
Cancer Chemother Pharmacol; 2003 Apr; 51(4):328-36. PubMed ID: 12721761
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of serum iohexol clearance for use in predicting carboplatin clearance in cats.
Bailey DB; Rassnick KM; Prey JD; Dykes NL
Am J Vet Res; 2009 Sep; 70(9):1135-40. PubMed ID: 19719430
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer.
Fogli S; Danesi R; Gennari A; Donati S; Conte PF; Del Tacca M
Ann Oncol; 2002 Jun; 13(6):919-27. PubMed ID: 12123338
[TBL] [Abstract][Full Text] [Related]
18. Predicting Chemotherapy-Induced Neutropenia and Granulocyte Colony-Stimulating Factor Response Using Model-Based In Vitro to Clinical Translation.
Chen W; Boras B; Sung T; Hu W; Spilker ME; D'Argenio DZ
AAPS J; 2020 Nov; 22(6):143. PubMed ID: 33156437
[TBL] [Abstract][Full Text] [Related]
19. A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC).
Rodon J; Jacobs CD; Chu Q; Rowinsky EK; Lopez-Anaya A; Takimoto CH; Wakelee HA
Cancer Chemother Pharmacol; 2012 Mar; 69(3):825-34. PubMed ID: 22057853
[TBL] [Abstract][Full Text] [Related]
20. Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy.
Flaherty KT; Stevenson JP; Hahn SM; Redlinger M; O'Dwyer PJ
Cancer Chemother Pharmacol; 2003 Sep; 52(3):217-22. PubMed ID: 12811513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
